Descripción de la empresa
Apollomics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of oncology therapies designed to harness the immune system and target specific molecular pathways for cancer inhibition. The company functions within the Healthcare sector, specifically the Biotechnology industry, a domain characterized by high-risk research and development activities aimed at bringing novel treatments to market. Its current operational scale is defined by a market capitalization of $31.46M, annual revenue of $6.93M, and an employee count of 13 individuals. These valuation and revenue figures indicate that Apollomics, Inc. occupies a small-cap position within the biotechnology landscape, suggesting limited resources relative to large-cap peers but potentially high growth potential if its clinical-stage products successfully advance through development pipelines.
Salud financiera
The company reported revenue of $6.93M over the trailing twelve months, yet this figure masks a significant operational challenge revealed by a net income loss of $31,188,000 and an EBITDA of $-26,359,000. The substantial gap between the positive revenue figure and the deeply negative net income highlights an aggressive cost structure where operating expenses, likely driven by research and development and general administrative costs, far exceed current sales generation. Furthermore, the company generated a free cash flow of $-14,440,000, which indicates a lack of financial flexibility as current cash generation is insufficient to cover operational burn without external capital infusion. Margin analysis reveals a gross margin of 100.0%, typical for companies with minimal cost of goods sold in early-stage development, contrasted sharply by an operating margin of -124.8% and a profit margin of 0.0%, both signaling that overhead costs are consuming all revenue and exceeding it. Regarding balance sheet leverage, the company holds $2.10M in cash against $744,000 in debt, while the debt-to-equity ratio is N/A due to the negative equity position implied by the losses. The current ratio stands at 0.97, indicating that the company's current assets do not fully cover its current liabilities, presenting a moderate short-term liquidity risk. Finally, the return on equity is -380.1% and the return on assets is -72.3%, metrics that reveal management has yet to generate positive returns on shareholder or asset investments due to the cumulative nature of pre-revenue losses.
Evaluación de valoración
Valuation metrics for Apollomics, Inc. reflect its pre-profitability status, with a P/E ratio (TTM) of N/A and a forward P/E of -22.54. The absence of a trailing P/E and the negative forward P/E imply that the market is not pricing the stock based on current or near-term earnings power, as expected earnings are negative and will likely remain so in the near term. The price-to-book ratio is -3.68, a figure that indicates the market values the company at a negative premium relative to its book value, a common characteristic for biotechnology firms with significant intangible assets or R&D expenditures not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio of 4.54 and an EV/EBITDA of -0.56 suggest the market is valuing the firm primarily on its pipeline potential rather than current financial performance, assigning a multiple that is high relative to sales but distorted by negative earnings. In terms of price action, the stock has traded between a 52-week low of $3.66 and a 52-week high of $42.12. The current trading price sits significantly below the 52-week high, reflecting the volatility and risk premium associated with clinical-stage development, though the exact percentage distance from the high fluctuates with daily market movements. The beta of 1.83 indicates that the stock exhibits high price volatility, moving with greater intensity than the broader market index, which is consistent with small-cap biotechnology stocks that are sensitive to regulatory news and clinical trial outcomes.
Growth & Income
Revenue growth for Apollomics, Inc. accelerated significantly with a year-over-year increase of 380.8%, whereas earnings growth is N/A due to the company's continued net losses. The disparity between high revenue growth and stagnant (negative) earnings growth implies that recent sales increases are being absorbed by ongoing expenses required to advance the company's oncology therapies through clinical stages. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available capital is being reinvested into research, development, and operational scaling rather than distributed to shareholders. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies that prioritize long-term product development over immediate income generation. Overall, the company's growth and income profile is characterized by rapid top-line expansion funded by cash reserves, with no current distribution of income to investors, reflecting a high-risk, high-reward asset class focused entirely on future therapeutic potential.